Mumbai, Maharashtra, 11th of April, 2026 : Amid the rapidly rising cases of high blood pressure in India, a significant step has been taken to make treatment simpler and more effective. Cadila Pharmaceuticals has launched a new triple combination therapy called ‘Silej Trio’, which brings together three powerful medications in a single pill. This innovative approach not only aims to control blood pressure more effectively but also simplifies medication routines for patients. It offers new hope, especially for those struggling with long-term hypertension and cardiovascular conditions.
India has nearly 220 million people affected by high blood pressure, yet lack of timely diagnosis and consistent treatment often worsens the condition. In this context, ‘Silej Trio’ emerges as an advanced fixed-dose combination that integrates three well-established drugs—Cilnidipine, Telmisartan, and Metoprolol—into one tablet.
This combination works through three different mechanisms: relaxing blood vessels, regulating hormonal activity, and stabilizing heart rate. Notably, it claims better tolerability and fewer side effects compared to conventional therapies, including a significantly lower risk of leg swelling.
Built on Tri-Tab technology, the drug features a three-layered structure that enhances absorption and ensures sustained release in the body. This not only helps maintain consistent blood pressure control but also provides added cardiac protection. Experts believe that such combination therapies could play a key role in making hypertension management more effective, safer, and convenient in the future.
About The Author
More Stories
Union Minister Shri Rajiv Ranjan Singh Chairs Seafood Exporters Meet 2026 In New Delhi; Chart Strategy To Expand Global Market Reach.
From Queues To QR Codes: India’s Payment Revolution.
Shri Nandamuri Balakrishna Inaugurates The Prestigious ISDE India Edition 2026, On Esophageal Cancer, Being Held For The First Time In India.